Publications by authors named "R Falahati"

This study was performed to determine the early-life (first month of age) supplementation of liquid feed with fennel seed powder (FSP) or oregano leaf powder (OLP) on growth performance, health, and blood biochemical attributes in preweaning dairy calves. Holstein female calves (n = 57; 1 d of age; 34.1 ± 0.

View Article and Find Full Text PDF

Siglecs (sialic acid-binding immunoglobulin-like lectins) are single-pass cell surface receptors that have inhibitory activities on immune cells. Among these, Siglec-8 is a CD33-related family member selectively expressed on human mast cells and eosinophils, and at low levels on basophils. These cells can participate in inflammatory responses by releasing mediators that attract or activate other cells, contributing to the pathogenesis of allergic and non-allergic diseases.

View Article and Find Full Text PDF

In addition to their well characterized role in mediating IgE-dependent allergic diseases, aberrant accumulation and activation of mast cells (MCs) is associated with many non-allergic inflammatory diseases, whereby their activation is likely triggered by non-IgE stimuli (e.g., IL-33).

View Article and Find Full Text PDF

Aberrant accumulation and activation of eosinophils and potentially mast cells (MCs) contribute to the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), including eosinophilic esophagitis (EoE), gastritis (EG), and gastroenteritis (EGE). Current treatment options, such as diet restriction and corticosteroids, have limited efficacy and are often inappropriate for chronic use. One promising new approach is to deplete eosinophils and inhibit MCs with a monoclonal antibody (mAb) against sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8), an inhibitory receptor selectively expressed on MCs and eosinophils.

View Article and Find Full Text PDF
Article Synopsis
  • AK002 is a targeted antibody being studied for treating allergic and inflammatory diseases by specifically engaging Siglec-8, which is found on mast cells and eosinophils, leading to their apoptosis and reduced activation.
  • The study assessed AK002's effectiveness in various models, showing it binds selectively to relevant cells, induces cell death in activated eosinophils, and enhances immune responses through antibody-dependent cell-mediated cytotoxicity (ADCC).
  • Results indicate that AK002 can significantly lower eosinophil levels in human lung tissues and help prevent severe allergic reactions in mouse models, suggesting its potential as a therapeutic option for related diseases.
View Article and Find Full Text PDF